Percutaneous heart valve interventions: a South African perspective
For nearly four decades open prosthetic valve replacement has been the only option for most of these patients, but in 2000 Phillip Bonhoeffer replaced the fi rst heart valve (a pulmonary valve) percutaneously (3) and in 2002, Cribier performed the fi rst percutaneous replacement of an aortic valve. (4) Percutaneous heart valve replacement has enjoyed a lot of interest with numerous new developments since then. This paper will discuss these developments and their relevance to South Africa.
BALLOON MITRAL VALVOTOMY
Balloon mitral valvotomy (BMV) for rheumatic mitral stenosis is widely used throughout South Africa and there is considerable local expertise for this procedure. The technical aspects of the procedure are beyond the scope of this review and will not be discussed. 
INTRODUCTION
Valvular heart disease represents a signifi cant health care problem worldwide. More than 5 million Americans are diagnosed with heart valve lesions and 60 000 artifi cial valves are implanted annually in the USA. (1) The aetiology of valve disease in the developed world is predominantly degenerative.
Research and technical advances in valve replacement surgery are therefore mainly focused on degenerative valve disease.
Typical degenerative valve lesions are senile aortic stenosis (AS) and mitral valve regurgitation (MR) due to prolapse.
These developments may not be as relevant in the South
African context where the aetiology of valve disease is frequently rheumatic and the affected patient population is much younger. The prevalence of rheumatic heart disease in South Africa is unknown; a prevalence of 0.69% has been reported for children, rising to 2% for children 12-14 years of age. (2) Rheumatic heart disease typically results in mitral stenosis (MS) and MR, and the latter, when present, has a completely different mechanism to the causes of MR mostly seen in developed countries. 
Patient Selection
Several studies have documented the excellent long-term outcome of the minimally invasive BMV procedure. (5, 6) In a series of 1 024 patients followed up for a median of 49 months, the 10-year actuarial rate for survival free of surgery or repeat dilatation was 67 % for the patients who had a good immediate result. Pre-procedural patient selection is pivotal to achieving a good immediate result.
The following factors were identifi ed as predictors of a poor longterm result after BMV: Echocardiographic evaluation of the mitral valve is essential for correct patient selection. A number of scoring systems have been developed to improve patient selection. The morphology of the subvalvular apparatus, the presence of commissural fusion and the presence of calcifi cation are included in most scoring systems. A well validated example is the Massachusetts General Hospital Score. (8) A score of <9 in association with no more than mild MR, is associated with a good short term outcome following the procedure. (9, 10) The following clinical settings are of interest:
Pregnancy
Mitral stenosis is a relatively common valve lesion in young pregnant South Africans and is poorly tolerated during the second and third trimester of gestation and during labour.
Ideally, pregnancy should be postponed until after treatment of the valve lesion and planned in conjunction with the patient's cardiologist. In South Africa, however, patients are frequently only seen in their mid-or last trimester with severe MS. In pregnancy, a valve area below 1,5cm 2 is haemodynamically signi- (11) 
Thrombus in left atrium
The American Heart Association / American College of Cardiologists' guidelines for BMV require the absence of a thrombus in the left atrium (LA) because of the risk of embolisation. (15) Trans-oesophageal echo (TEE) is more sensitive than transthoracic echo to screen patients for the presence a LA thrombus. Risk factors for the presence of thrombus includes older age, atrial fi brillation, LA size and smaller valve area. (16) Patients in whom a thrombus is detected receive anticoagulation therapy for 3 months. BMV can be performed safely once the thrombus has been resolved. (17) BMV is not performed in cases where the thrombus has not resolved after 3 months of anti-coagulation therapy, unless the patient is a poor surgical 
Edge-to-edge repair
Since Alfi eri introduced this surgical technique in 1991, a great deal of experience has been gained and in their hands up to 95% of patients do not require repeat surgery at 4 years. Edgeto-edge repair involves suturing the central portion of the two mitral valve leafl ets together to create a double orifi ce. This prevents prolapse of the one leafl et and does not impair diastolic fi lling. (21) To date the Evalve Mitraclip™ (Evalve Inc., Menlo Park, CA) system has the most data and experience of the percutaneous techniques that evolved from Alfi eri's surgical PERCUTANEOUS HEART VALVE INTERVENTIONS FIGURE 1: Diagrammatic representation of a coronary sinus percutaneous mitral annuloplasty device. On the left is the catheter based device being inserted into the coronary sinus and on the right it is after deployment. The Evalve Mitraclip™ device was tested in the EVEREST I trial (a multi-centre feasibility trial) where clips were implanted in 24 patients. One month post procedure only 18 patients were free from surgery, but successful results were maintained at six months post procedure. (22) The much larger multi-centre EVEREST II trial planned to complete enrollment by the end of 2008.
The following factors could limit the future use of the above mentioned devices:
The complexity of the procedure and small number of referral centers with experience in performing the procedure.
It will be diffi cult for the percutaneous procedures to match the excellent surgical results with up to 30 year follow-up data.
The regulatory approval of the devices may take too long.
An isolated edge-to-edge repair is unlikely to be suffi cient in patients with annulus dilatation, which represents 90% of cases currently referred for surgery to the Alfi eri group. (21) This rather pessimistic view must be tempered by the fact that, 
The procedure is currently not suitable for application in humans, but the concept may prove useful in future.
AORTIC STENOSIS
Isolated AS is typically due to degenerative changes or to congenital bicuspid aortic valve deformities. Many patients are elderly with a multitude of co-morbid conditions that increases
the risk of open heart surgery. In Europe, up to one third of potential candidates are consequently not offered valve surgery.
This is in spite of numerous advances and excellent long term results in aortic valve replacement surgery. (24) Balloon valvotomy has been the initial procedure in percutaneous aortic valve interventions. This procedure has been unsuccessful due to a high rate of acute embolisation resulting in stroke and a high re-stenosis rate at short term (six months) follow-up. (25) Transcatheter aortic valve implantation (TAVI) experiments were fi rst published in 1992. (26) Bonhoeffer implanted a bovine jugular vein valve that was sutured onto a stent in the descending aorta of lambs in 2002. (27) Inserting a stented valve in the sub coronary position without obstructing the coronary ostia has proven diffi cult in animal studies. (28) In humans, however, the rim of calcifi ed tissue between the valve and the aortic wall probably acts as a barrier, preventing coronary obstruction. Since Alain Two major approaches are used with metal stents: balloon expandable or self expanding Nitinol stents. It is important to note that no valve has been approved by the FDA for use in humans, other than in an investigational setting.
Numerous groups have described experience in animals and
Grube recently published the fi rst implantation of the Sadra Medical Lotus valve TM . (29) This discussion will however focus on the designs with the most human experience.
SAPIEN VALVE
The Cribier-Edwards™ valve ( Figure 3 ) and its updated version, rates have also increased due to refi nement of the delivery system. (31, 32) The trans-apical approach is used in patients with inaccessible femoral arteries. A small antero-lateral thoracotomy is performed (from 53+/-15% to 57+/-13%), mitral regurgitation grade (from 2 to 1) and functional class. Improvement was maintained at one year. Two patients suffered strokes during the procedure. (32) More recently they have also reported no evidence of structural valve deterioration beyond 2 years. (30) In the data presented by Martin Leon at EuroPCR 07, the average logistic Euro SCORE was 33% but in the 55 patients treated in the REVIVAL II study, 6 month mortality was only 16% (unpublished data).
With the trans-apical approach, Webb et al. described their fi rst seven cases with 6/7 patients alive at 3 months and signifi cant haemodynamic improvement in all patients. (35) In the largest published series of 59 cases with an average Euro SCORE predicted risk of 27+/-14%, Walther et al. demonstrated a 13%
in-hospital mortality. Valve positioning was performed successfully in 53 patients. Four patients required early conversion to sternotomy and mild AR was present in 25% of cases. (36) Although it was initially thought that this approach would lead to lower risk of peri-procedural stroke, both approaches have a similar published stroke rate of +/-4%. (37, 38) 
COREVALVE REVALVING SYSTEM TM
The fi rst percutaneous aortic valve replacement with a self In 64% of these, they could deploy the valve without hemo- 
Clinical experience
In the most experienced centre, acute device success was 88% with 6 devices misplaced and 2 cases where the device would not cross the native valve. Overall 30-day mortality was 12%
(mean logistic Euro SCORE was 23%). 
Despite receiving CE approval recently, the CoreValve ReValving™ system has not been released onto the market but is proceeding with an expanded clinical evaluation and is not available in the USA. CT-angiography is recommended in addition to echocardiography to evaluate the above structures, and for assessing the possibility of obstruction of the left main coronary artery. These devices were developed for AS and their experience in patients with predominant AR is limited. (48) Paravalvular AR has been reported in most series (4, 33, 42, 49) but with routine oversizing and accurate placement of the device the majority of leaks are mild and well tolerated 50. In vitro valve testing anticipates durability comparable to many conventional bio-prostheses. (30) Although structural valve deterioration has not been reported, limited late follow-up data is available. (31, 38, 42) Survival without structural failure has been reported for up to 4 years. One can conclude that the future is (almost) here, but that South Africans would probably have to wait a bit longer. Issues that need to be addressed are cost, adequate training and regulation.
Patient selection for TAVI
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